Telomir Q3 Loss Narrows to $0.7M; Cash Runway Extended Into Q4 2027
TELO is trading near its 52-week low of $0.693 (6.7% above the low).
Summary
Telomir's Q3 10-Q shows a narrower $0.7M quarterly loss and extends its stated cash runway into Q4 2027, though the going-concern warning remains and share count has ballooned from the TELI merger and October private placement.
Key Events · Earnings and Guidance · TELO
-
Q3 Loss Narrows, Runway Extended
Net loss was $705,225 for the three months ended September 30, 2026 versus $1,102,294 a year earlier; nine-month loss fell to $3,417,700 from $8,352,012. Management now expects cash to fund operations into the fourth quarter of 2027.
-
Going Concern Still Flagged
The filing states the company does not have sufficient cash on hand for the 12 months following issuance and that substantial doubt exists about its ability to continue as a going concern absent new financing.
-
October Placement Adds $5.7M Gross
Subsequent to quarter-end, Telomir sold 4,900,750 shares at $1.13-$1.16 for about $5.7M gross, before roughly $530,000 of placement agent fees and expenses, and issued 392,060 placement agent warrants.
-
TELI Merger Drives Share Count Up
The April 22, 2026 related-party merger added 34,389,710 shares valued at $47.1M ($1.37 per share), producing a $46,113,903 deemed dividend; shares outstanding rose to 68,774,956 at September 30, 2026 from 34,380,971 at December 31, 2025.
Analysis · TELO · Life Sciences
The going-concern warning persists, but the runway story has improved: management now says $4.5M of cash plus the October private placement will fund operations into the fourth quarter of 2027, versus the prior 10-Q's runway only through Q1 2027. That buys roughly three extra quarters before the company must raise again, and the quarter itself was cheaper — a $0.7M net loss versus $1.1M a year ago, with nine-month losses down to $3.4M from $8.4M as stock compensation fell sharply. The offset is dilution already incurred: 34,389,710 shares issued for the related-party TELI merger (a $46.1M deemed dividend) and 4,900,750 shares sold in October at $1.13-$1.16, well below today's $0.74 only in the sense that the stock has since fallen — the placement was priced at a 5% discount to the 10-day VWAP at the time. The $3.5M Chapman estate claim remains unaccrued and unresolved.
How filings like this one have moved
In the 30 days to Nov 6, 2026, 45% of the 1400 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.36%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TELO was trading at $0.74 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $52.3M. The 52-week trading range was $0.69 to $1.58. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.